News

BlinkRx Partners with ARS Pharmaceuticals for neffy® Launch

BlinkRx Partners with ARS Pharmaceuticals for neffy® Launch

BlinkRx Collaborates with ARS Pharmaceuticals to Introduce neffy®

BlinkRx, a pioneering patient access platform, has recently joined forces with ARS Pharmaceuticals to enhance patient care with the introduction of neffy®, an innovative needle-free epinephrine nasal spray. This groundbreaking treatment represents a significant advancement in the management of Type I allergic reactions, including life-threatening anaphylaxis.

Unveiling the Advantages of neffy®

neffy® is unique as the first and only needle-free treatment developed for those experiencing severe allergic reactions. It is specifically designed for individuals weighing 30 kgs (66 lbs) or more, making it a versatile option for both children and adults. Patients prescribed neffy® can now easily access this medication via the BlinkRx platform, which prioritizes transparent pricing, free home delivery, and personalized support for each patient's needs.

Understanding the Impact of Allergy Reactions

In the United States, around 40 million individuals suffer from Type I allergic reactions caused by various triggers, including food allergies and insect venom. Despite this alarming number, only a fraction—about 3.3 million—fill prescriptions for epinephrine devices annually, and less than half consistently carry the devices in emergencies. Concerningly, Type I allergic reactions contribute to up to 500,000 emergency room visits each year.

Addressing Critical Needs with Innovative Solutions

By providing neffy®, BlinkRx aims to reduce the barriers to treatment during critical moments when prompt action is necessary. The user-friendly design of neffy® allows caregivers and patients to respond effectively in emergencies, thereby increasing the likelihood of timely administration of epinephrine.

Quotes from Key Executives

Richard Lowenthal, CEO and President of ARS Pharmaceuticals, shares his enthusiasm, stating, "We’re thrilled to make neffy® available through BlinkRx so people with severe allergic reactions can have a needle-free option for treating symptoms of anaphylaxis." He further emphasizes the partnership: "Through neffyConnect and in collaboration with BlinkRx, eligible commercially insured patients can obtain two neffy® devices at a co-pay of $25. For those without insurance or with plans that exclude neffy®, we are pleased to offer a cash price of $199."

Geoffrey Chaiken, CEO of Blink Health, expressed his commitment to patient access, noting, "At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. Making neffy® available on our platform enhances the accessibility of epinephrine for patients in need, particularly for underserved communities."

About BlinkRx and Its Revolutionary Approach

BlinkRx is at the forefront of reshaping the pharmacy experience by leveraging advanced technology to greatly improve patient access to branded medications. The company provides healthcare providers with dedicated access teams and comprehensive authorization support to facilitate patient care. In addition, patients benefit from affordable and transparent pricing, co-pay assistance, free home delivery options, and dedicated support tailored to individual needs.

Learn More

To discover more about the services offered by BlinkRx and the benefits of using their platform to access healthcare solutions, visit their official website and view their resources designed for both patients and healthcare professionals.

Frequently Asked Questions

What is neffy®?

neffy® is a needle-free epinephrine nasal spray designed for treating severe allergic reactions, including anaphylaxis.

Who can use neffy®?

neffy® is available for patients who weigh 30 kgs (66 lbs) or more, applicable for both children and adults.

How does BlinkRx facilitate access to neffy®?

BlinkRx allows patients to access neffy® with transparent pricing, free home delivery, and personalized support.

What partnerships support the launch of neffy®?

BlinkRx has partnered with ARS Pharmaceuticals to provide neffy® efficiently through its platform.

What are the financial options available for neffy®?

Insured patients may pay a co-pay of $25 for neffy®, while non-insured patients can access it for a cash price of $199.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tragedy Highlights Need for E-bike Safety Overhaul

Updated Category News Views 5

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...

Continue Reading
Papa John's Faces Class Action Over Misleading Info

Updated Category News Views 5

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Continue Reading
Quay Dominates 2026 Sunglasses Review for Variety

Updated Category News Views 4

Sunglasses Designed for Every Face Type When it comes to picking the right pair of shades, face shape is only part of the equation. Expert Consumers just dropped their 2026 verdict, spotlighting Quay as the go-to brand for those wider faces, tricky nose bridges, and the noggins that run a tad larger than average. Forget what you heard about one-size-fits-all. This...

Continue Reading
BarrelPick.com Launches for Bourbon Aficionados

Updated Category News Views 4

Just when you think you've seen all the ways to enjoy bourbon, along comes BarrelPick.com with a tantalizing new proposition. They're throwing down the gauntlet for bourbon lovers everywhere by letting you buy an entire barrel, let it sit around for a bit, watch it mature, and then call the shots on when it finally sees the light of day in a bottle. Talk about skipping...

Continue Reading
GAC's Cambodia Plant: A Strategic Manufacturing Shift

Updated Category News Views 3

Setting the Stage for New Industrial Growth On September 17, a milestone was etched in the sands of Cambodia when the GAC Cambodia KD Plant officially flipped the switch. This ain't just another factory throwing doors open; it's a fresh chapter in regional manufacturing power plays. We had some big hitters in attendance, like Cambodian Prime Minister Hun Manet, showing...

Continue Reading
2026 Lantern Festival Shines in Kunshan Amid Tensions

Updated Category News Views 4

Lanterns Illuminate Cross-Strait Relations Under the shadow of geopolitical tensions, the 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival kicked off with a splash on September 16. Held in Kunshan, Suzhou, this cultural festival offers a rare glimpse of cooperation and shared cultural celebration across the Taiwan Strait. Through lantern displays, art exhibitions,...

Continue Reading
Chery Auto's Bold Green Tech Showcase at 2026 Summit

Updated Category News Views 3

Chery Auto Puts Eco Tech at Front and Center You know, Chery Auto isn't just manufacturing cars anymore—it's shaping an entire lifestyle. For the uninitiated, they’re calling in everyone worth knowing to their headquarters in Wuhu, China, come October 18 through 24. The 2026 Chery International User Summit is kind of a big deal this year with nearly 20 new green...

Continue Reading
USPS Rolls Out Christmas Cookie Stamps Nationwide

Updated Category News Views 5

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Continue Reading
Xi Jinping Thought: A Bold Prospect for Future Governance

Updated Category News Views 5

107 years in the game, and the Communist Party of China (CPC) isn't showing any signs of slowing. With their recent conference in Beijing focusing on Xi Jinping Thought on Party Building, it’s clear they’ve got their eyes on the future, not just resting on past laurels. This Xi Jinping Thought is about a thorough self-improvement plan for the Party, a clear strategy...

Continue Reading
China's Tech Success Echoes in Global Living Rooms

Updated Category News Views 4

A New Player in Global Tech If you've been sleeping on China's tech scene, it's time to wake up. Moonshot AI just launched Kimi K3, the largest open-source model by parameters we've seen, a significant leap in artificial intelligence that's catching even the eyes of folks who hardly touch technology—like retirees in Italy. Rapid AI Advancements China's story isn't about...

Continue Reading

Top 5 Most Recently Viewed Articles

Reverie Shifts Focus to Broaden Community Appeal

Updated Category News Views 6

Shifting Horizons in Home Development There's a new wave sweeping the community development market, where age-based living is getting a makeover under the influence of shifting buyer preferences. Dream Finders Homes saw it coming and decided to tweak their Reverie brand to better fit this new mold. The name of the game now is lifestyle, wellness, and social engagement...

Continue Reading
Silicon Quantum Computing Advances Quantum Technologies Further

Updated Category News Views 127

Silicon Quantum Computing Advances in Quantum Benchmarking Silicon Quantum Computing (SQC) has reached a major milestone by being selected by the Defence Advanced Research Projects Agency (DARPA) to progress to the next stage of the Quantum Benchmarking Initiative (QBI). This achievement confirms the potential of SQC's unique approach to developing quantum computers...

Continue Reading
Understanding the Rise in Short Interest for WMS Stock

Updated Category News Views 152

Insights Into the Recent Surge of Short Interest for WMS Advanced Drainage Systems has recently seen an uptick in its short interest, with reports indicating that 19.58% of its float is now sold short. With approximately 2.62 million shares being shorted, this represents about 3.42% of its available trading shares. Given the current trading volumes, it is estimated that...

Continue Reading
Olema Oncology Grants New Stock Options to Employees

Updated Category News Views 184

Olema Oncology Initiates Stock Option Grants Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a pioneering clinical-stage biopharmaceutical company, recently took a significant step in its growth strategy by granting stock options to new employees. This decision reflects Olema's commitment to fostering talent while enhancing its innovative...

Continue Reading
Community Heritage Financial Announces Upcoming Dividend Payout

Updated Category News Views 101

Community Heritage Financial Dividend Announcement Community Heritage Financial, Inc. (OTCPK: CMHF) recently declared that its Board of Directors approved a quarterly cash dividend of $0.08 per share on its common stock. This is a significant announcement for shareholders, highlighting the company’s ongoing commitment to return value to its investors. Details of the...

Continue Reading